Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NDV01 intravesical therapy in high-grade non-muscle-invasive bladder cancer
MOH_2024-06-01_013444Phase 2Not yet recruiting
- Sponsor
- Trigone Pharma
- Start
- May 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NDV-01, gemcitabine, docetaxel and carbomer 974P in bladder cancer and non-muscle-invasive bladder cancer (NMIBC), sponsored by Trigone Pharma. Planned start May 2024; status: not yet recruiting.
02
Drugs
NDV-01gemcitabinedocetaxelcarbomer 974P
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on MOH_2024-06-01_013444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-06-01_013444.